PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/35, C07D 311/58

A1

(11) International Publication Number: WO 00/12086

(43) International Publication Date: 9 March 2000 (09.03.00)

(21) International Application Number: PCT/US99/19062

(22) International Filing Date: 18 August 1999 (18.08.99)

(30) Priority Data:

60/098,341	28 August 1998 (28.08.98)	US
09/334,276	16 June 1999 (16.06.99)	US

(71) Applicant *(for all designated States except US)*: BIOMEDICINES, INC. [US/US]; 1301 Marina Village Parkway #200, Alameda, CA 94501 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: MORAN, Stanford, Mark [US/US]; 55 Orinda View Road, Orinda, CA 94563 (US).

(74) Agents: MORAN, Tom, M.; Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306-2155 (US) et al.

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD OF MITIGATING THE ADVERSE EFFECTS OF INTERLEUKIN-2

(57) Abstract

A method and composition for mitigating the adverse effects of Interleukin-2 (IL-2) on a subject is disclosed. The method involves administering an amount of a leukotriene receptor antagonist to a subject exhibiting adverse pharmacological effects due to exogenous IL-2, where the amount administered to the subject is sufficient to decrease the IL-2 induced adverse effects. Also disclosed is an article of manufacturing comprising a composition of the leukotriene receptor antagonist in combination with labeling instructions for treatment. Also disclosed is a method for preparing a pharmaceutical composition.